Epidemiology and Natural History of NAFLD and NASH

Clinics in Liver Disease

Volumn 11, Issue 1, 2007, Pages 1-16

  Ong, Janus P ^a   Younossi, Zobair M ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; LIVER ENZYME;

AGE DISTRIBUTION; ALCOHOL ABUSE; CANCER SCREENING; CARDIOVASCULAR DISEASE; CHRONIC LIVER DISEASE; DIABETES MELLITUS; DISEASE COURSE; FATTY LIVER; HEPATITIS; HUMAN; HYPERTRIGLYCERIDEMIA; INCIDENCE; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; METABOLIC SYNDROME X; MORTALITY; NONALCOHOLIC FATTY LIVER; OBESITY; PREVALENCE; PROGNOSIS; RACE DIFFERENCE; REVIEW; RISK FACTOR; SEX DIFFERENCE; WEIGHT GAIN;

FATTY LIVER; HEPATITIS; HUMANS; RISK FACTORS;

EID: 34249668818     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.02.009     Document Type: Review

References (79)

1. McCullough A.J. The epidemiology and risk factors of NASH. In: Farrell G.C., George J., de la M Hall P., et al. (Eds). Fatty liver disease: NASH and related disorders (2005), Blackwell Publishing, Malden (MA) 23-37
2. Mofrad P., Contos M.J., Haque M., et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37 6 (2003) 1286-1292
3. Ong J.P., Elariny H., Collantes R., et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 15 3 (2005) 310-315
4. Clark J.M., Brancati F.L., and Diehl A.M. The prevalence and etiology of elevated aminotransferase levels in the united states. Am J Gastroenterol 98 5 (2003) 960-967
5. Prati D., Taioli E., Zanella A., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137 1 (2002) 1-10
6. Ruhl C.E., and Everhart J.E. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the united states. Gastroenterology 124 1 (2003) 71-79
7. Clark J.M., Brancati F.L., and Diehl A.M. Nonalcoholic fatty liver disease. Gastroenterology 122 6 (2002) 1649-1657
8. Saadeh S., Younossi Z.M., Remer E.M., et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123 3 (2002) 745-750
9. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the united states: impact of ethnicity. Hepatology 40 6 (2004) 1387-1395
10. Suzuki A., Angulo P., Lymp J., et al. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology 41 1 (2005) 64-71
11. Hamaguchi M., Kojima T., Takeda N., et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143 10 (2005) 722-728
12. Omagari K., Kadokawa Y., Masuda J., et al. Fatty liver in non-alcoholic non-overweight japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol 17 10 (2002) 1098-1105
13. Ground K.E. Liver pathology in aircrew. Aviat Space Environ Med 53 1 (1982) 14-18
14. Hilden M., Christoffersen P., Juhl E., et al. Liver histology in a 'normal' population-examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 12 5 (1977) 593-597
15. Nomura H., Kashiwagi S., Hayashi J., et al. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 27 2 (1988) 142-149
16. Shen L., Fan J.G., Shao Y., et al. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol 9 5 (2003) 1106-1110
17. Lai S.W., Tan C.K., and Ng K.C. Epidemiology of fatty liver in a hospital-based study in Taiwan. South Med J 95 11 (2002) 1288-1292
18. Nonomura A., Mizukami Y., Unoura M., et al. Clinicopathologic study of alcohol-like liver disease in non-alcoholics; non-alcoholic steatohepatitis and fibrosis. Gastroenterol Jpn 27 4 (1992) 521-528
19. Bedogni G., Miglioli L., Masutti F., et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the dionysos nutrition and liver study. Hepatology 42 1 (2005) 44-52
20. Farrell G.C., and Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 2 Suppl 1 (2006) S99-S112
21. Ioannou G.N., Boyko E.J., and Lee S.P. The prevalence and predictors of elevated serum aminotransferase activity in the united states in 1999-2002. Am J Gastroenterol 101 1 (2006) 76-82
22. Kojima S., Watanabe N., Numata M., et al. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 38 10 (2003) 954-961
23. Liangpunsakul S., and Chalasani N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third national health and nutrition survey (NHANES III). Am J Med Sci 329 3 (2005) 111-116
24. Kemmer N.M., McKinney K.H., Xiao S.Y., et al. High prevalence of NASH among Mexican-American females with Type II diabetes mellitus (2001), W.B. Saunders, Philadelphia p. A117
25. Dixon J.B., Bhathal P.S., and O'Brien P.E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121 1 (2001) 91-100
26. Daniel S., Ben-Menachem T., Vasudevan G., et al. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 94 10 (1999) 3010-3014
27. Skelly M.M., James P.D., and Ryder S.D. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 35 2 (2001) 195-199
28. Crespo J., Fernandez-Gil P., Hernandez-Guerra M., et al. Are there predictive factors of severe liver fibrosis in morbidly obese patients with non-alcoholic steatohepatitis?. Obes Surg 11 3 (2001) 254-257
29. Fan J.G., Zhu J., Li X.J., et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 43 3 (2005) 508-514
30. Kagansky N., Levy S., Keter D., et al. Non-alcoholic fatty liver disease-a common and benign finding in octogenarian patients. Liver Int 24 6 (2004) 588-594
31. Weston S.R., Leyden W., Murphy R., et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 41 2 (2005) 372-379
32. Caldwell S.H., Harris D.M., Patrie J.T., et al. Is NASH underdiagnosed among African Americans?. Am J Gastroenterol 97 6 (2002) 1496-1500
33. Falck-Ytter Y., Younossi Z.M., Marchesini G., et al. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 21 1 (2001) 17-26
34. Marchesini G., Bugianesi E., Forlani G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37 4 (2003) 917-923
35. Pagano G., Pacini G., Musso G., et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 35 2 (2002) 367-372
36. Ludwig J., Viggiano T.R., McGill D.B., et al. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55 7 (1980) 434-438
37. Lee R.G. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 20 6 (1989) 594-598
38. Powell E.E., Cooksley W.G., Hanson R., et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11 1 (1990) 74-80
39. Cortez-Pinto H., Camilo M.E., Baptista A., et al. Non-alcoholic fatty liver: another feature of the metabolic syndrome?. Clin Nutr 18 6 (1999) 353-358
40. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 6 (1999) 1413-1419
41. Angulo P., Keach J.C., Batts K.P., et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30 6 (1999) 1356-1362
42. Chitturi S., Abeygunasekera S., Farrell G.C., et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35 2 (2002) 373-379
43. Diehl A.M., Goodman Z., and Ishak K.G. Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 95 4 (1988) 1056-1062
44. Marchesini G., Brizi M., Morselli-Labate A.M., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107 5 (1999) 450-455
45. Ong J.P., and Younossi Z.M. Approach to the diagnosis and treatment of nonalcoholic fatty liver disease. Clin Liver Dis 9 4 (2005) 617-634 vi
46. Adams L.A., Sanderson S., Lindor K.D., et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42 1 (2005) 132-138
47. Harrison S.A., Torgerson S., and Hayashi P.H. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 98 9 (2003) 2042-2047
48. Day C.P. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 16 5 (2002) 663-678
49. Caldwell S.H., and Hylton A.I. The clinical outcome of NAFLD including cryptogenic cirrhosis. In: Farrell G.C., George J., de la M Hall P., et al. (Eds) (2005), Blackwell Publishing, Malden (MA) 168-180
50. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 1 (2005) 113-121
51. Teli M.R., James O.F., Burt A.D., et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 22 6 (1995) 1714-1719
52. Dam-Larsen S., Franzmann M., Andersen I.B., et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 53 5 (2004) 750-755
53. Ong J.P., and Younossi Z.M. Nonalcoholic fatty liver disease (NAFLD)-two decades later: are we smarter about its natural history?. Am J Gastroenterol 98 9 (2003) 1915-1917
54. Lindor K.D., Kowdley K.V., Heathcote E.J., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39 3 (2004) 770-778
55. Fassio E., Alvarez E., Dominguez N., et al. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40 4 (2004) 820-826
56. Calle E.E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348 17 (2003) 1625-1638
57. El-Serag H.B., Tran T., and Everhart J.E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126 2 (2004) 460-468
58. Ioannou G.N., Weiss N.S., Kowdley K.V., et al. Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study. Gastroenterology 125 4 (2003) 1053-1059
59. Villanova N., Moscatiello S., Ramilli S., et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42 2 (2005) 473-480
60. Targher G. Associations between liver histology and early carotid atherosclerosis in subjects with nonalcoholic fatty liver disease. Hepatology 42 4 (2005) 974-975 [discussion: 975]
61. Brea A., Mosquera D., Martin E., et al. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 25 5 (2005) 1045-1050
62. McPherson D.D. Circulatory dysfunction in NAFLD-which is first, which is last, and what do we do in between?. Hepatology 42 2 (2005) 270-272
63. Ratziu V., Bonyhay L., Di Martino V., et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 35 6 (2002) 1485-1493
64. Hui J.M., Kench J.G., Chitturi S., et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 38 2 (2003) 420-427
65. Cotrim H.P., Parana R., Braga E., et al. Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history?. Am J Gastroenterol 95 10 (2000) 3018-3019
66. Zen Y., Katayanagi K., Tsuneyama K., et al. Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol Int 51 2 (2001) 127-131
67. Shimada M., Hashimoto E., Taniai M., et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 37 1 (2002) 154-160
68. Caldwell S.H., Oelsner D.H., Iezzoni J.C., et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29 3 (1999) 664-669
69. Poonawala A., Nair S.P., and Thuluvath P.J. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 32 4 Pt 1 (2000) 689-692
70. Ong J., Younossi Z.M., Reddy V., et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 7 9 (2001) 797-801
71. Bugianesi E., Leone N., Vanni E., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123 1 (2002) 134-140
72. Marrero J.A., Fontana R.J., Su G.L., et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the united states. Hepatology 36 6 (2002) 1349-1354
73. Ong J.P., and Younossi Z.M. Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis?. Gastroenterology 123 1 (2002) 375-378
74. Kim W.R., Poterucha J.J., Porayko M.K., et al. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 62 12 (1996) 1802-1805
75. Carson K., Washington M.K., Treem W.R., et al. Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient. Liver Transpl Surg 3 2 (1997) 174-176
76. Molloy R.M., Komorowski R., and Varma R.R. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation. Liver Transpl Surg 3 2 (1997) 177-178
77. Contos M.J., Cales W., Sterling R.K., et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 7 4 (2001) 363-373
78. Charlton M., Kasparova P., Weston S., et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 7 7 (2001) 608-614
79. Sutedja D.S., Gow P.J., Hubscher S.G., et al. Revealing the cause of cryptogenic cirrhosis by posttransplant liver biopsy. Transplant Proc 36 8 (2004) 2334-2337